Development of novel treatments for cardiac arrhythmia and hypertension

Beta-blockers such as propranolol are commonly used to treat cardiac arrhythmia and hypertension but have serious side effects; patients have a 5-year survival rate of 50%. New therapeutics for the treatment of these heart conditions are urgently needed.

We are currently studying the ability of four compound classes to prevent induction of the pro-apoptotic Bim protein but at the same time not affect CREB phosphorylation, a discovery which may be the key to the development of successful cardiac drug treatments.